Bando, Hiroshi Tokushima University|Japan Low Carbohydrate Diet Promotion Association|Sakamoto Hospital KAKEN Search Researchers
Iwatsuki, Noboru Sakamoto Hospital
Tanaka, Hisashi Higashikagawa city council
Sakamoto, Kazuki Sakamoto Hospital
Ogawa, Tomoya Sakamoto Hospital
Degludec and liraglutide (IDegLira)
Glucagon-like peptide 1 (GLP-1) receptor agonist (GLP-1RA)
DUAL (Dual Action of Liraglutide and Insulin Degludec)
European Xultophy Treatment Retrospective Audit (EXTRA)
The case is a 65-year-old male who has been treated for Type 2 diabetes mellitus (T2DM) for 26 years. He has no previous history of cerebral vascular accident (CVA) or coronary heart disease (CHD). He has been treated on insulin therapy, and recently his glucose variability became worse due to the irregular lifestyle. Then, diabetic treatment was changed to Xultophy, which consists of insulin degludec and liraglutide. Providing 16 units of Xultophy brought him a satisfactory daily profile of blood glucose, which seemed to be lower doses compared with the ordinary standard amount. Treatment of Xultophy seems to be effective and some discussion would be described from several points of view.
Biomedical Science Journal
Ciencia Scientific Publisher
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license(https://creativecommons.org/licenses/by/4.0/).
|DOI (Published Version)|
|URL ( Publisher's Version )|
bsj_2_1_BSJ-21-17.pdf 443 KB